Evaluation of therapeutic effectiveness of ulinastatin in acute pancreatitis by Syed Ibrahim Hassan & Syed Mohd Akbar Hassan
 
Asian Pac. J. Health Sci., 2016; 3(4S):27-33                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Hassan and Hassan        ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(4S):27-33 
www.apjhs.com      27 
 
Document heading        doi: 10.21276/apjhs.2016.3.4S.5                                                                     Research article 
Evaluation of therapeutic effectiveness of ulinastatin in acute pancreatitis 
1
Syed Ibrahim Hassan
*
, 
2
Syed Mohd Akbar Hassan 
1
Professor and HOD, Department of gastroenterology, Deccan College of medical sciences, Hyderabad, India 
2
Senior resident, Department of gastroenterology, Deccan College of medical sciences, Hyderabad, India 
 
ABSTRACT 
 
Introduction: Acute pancreatitis is an inflammatory condition of the pancreas which begins in pancreatic acinar 
cells and triggers local inflammation that may progress to systemic inflammatory response (SIRS) and causing 
distant organ involvement and its function and ending up with multiple organ dysfunction syndromes (MODS). 
Aim: To find out the effectiveness of addition of Ulinastatin to standard care in Indian subjects with acute 
pancreatitis. Methodology: A concurrent observational study is done to evaluate the effect of addition of Ulinastatin 
to the standard treatment and its efficacy to reduce the serum amylase and lipase levels in patients with Acute 
Pancreatitis. patients of both the genders i.e. male and female. Results: In the control groups 43 were males and 57 
were females. In the test group 47 were males and 53 females. Majority were in the age group between 30- 70 yrs of 
age with >50% in the 30-50 yrs age group in both tests and control group. Serum amylase the mean S.amylase: 
levels in control group was 686.16 units/l (day1), 515.72U/l (day2), 400.27 U/l (day 3), 296.42 U/l (day 4). whereas 
in the test group the mean amylase levels were 687.14 u/l (day 1), 233.83 u/l (day 2), 103.58 u/l (day3), 67.14 u/l 
(day 4) suggesting that after 5 days of therapy the amylase levels in the test groups touched normal values whereas 
in the control groups they were still high (>3 times) the normal (n-60 units/1l). The mean serum lipase levels in the 
control group at day 1 was 224.8 u/l, 142.93 u/l (day 2), 111.34 u/l (day3) and 82.78 u/l (day4).Where as in a test 
group the mean serum lipase level was 380.42 u/l (day1), 191.92 u/l (day 2), 91.58 u/l (day 3), 31u/l (day 4). The 
difference in the mean values between the control and test group for both serum amylase and serum lipase levels 
were found to be statistically very significant. On follow up after 5 days for a period of 2 weeks none of the patients 
in the test group developed any complication. Where as in the control group 12 patients developed pleural effusion, 
8-Pseudopancreatic cyst, 7- developed pancreatic pleural fistula which were treated symptomatically whereas in test 
group one patient developed pleural effusion and another pancreatic fistula symptomatically treated. Conclusion: 
The study concluded that addition of Ulinastatin to standard treatment of acute Pancreatitis is effective in reducing 
morbidity and mortality in Indian subjects. 
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Introduction 
 
Acute pancreatitis is an inflammatory condition of the 
pancreas which begins in pancreatic acinar cells and 
triggers local inflammation that may progress to 
systemic inflammatory response (SIRS) and causing 
distant organ involvement and its function and ending 
up with multiple organ dysfunction syndrome 
(MODS).Atlanta symposium definition of acute 
pancreatitis, which is an acute inflammatory process of 
the pancreas with variable involvement of other  
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regional tissues or remote organ systems. Acute 
pancreatitis is best defined clinically by a patient 
presenting with two of the following criteria: 
symptoms such as epigastric pain, consistent with the 
disease; a serum amylase or lipase greater than three 
times the upper limit of normal; or radiologic imaging 
consistent with the diagnosis, usually using computed 
tomography(CT) or magnetic resonance 
imaging(MRI).Premature activation of pancreatic 
zymogen is likely responsible for protease activated 
receptor- [PAR-2] which gets activated in the presence 
of trypsin resulting in production of cytokines and 
regulation of exocrine function through negative feed 
back loop. The pathophysiology of acute pancreatitis 
starts with local acinar injury that, if unchecked, leads 
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to local inflammatory complications, a systemic 
response and sepsis. Pathophysiological mechanisms 
include microcirculatory injury, leukocyte 
chemoattraction, release of pro and anti-inflammatory 
cytokines, oxidative stress, leakage of pancreatic fluid 
into the region of pancreas, and bacterial translocation 
to the pancreas and systemic circulation. The release of 
pancreatic enzymes damages the vascular endothelium, 
the interstitium, and acinar cells. Acinar cell injury 
leads to expression of endothelial adhesion molecules 
(eg., VCAM-1), which further propagates the 
inflammatory response. Microcirculatory changes, 
including vasoconstriction, capillary statis, decreased 
oxygen saturation and progressive ischemia, occur 
early in experimental acute pancreatitis. These 
abnormalities increase vascular permeability and 
edema of the gland(edematous or interstitial 
pancreatitis). Vascular injury could lead to local 
microcirculatory failure and amplification of pancreatic 
injury. Reperfusion of the damaged pancreatic tissue 
could lead to release of free radicals and inflammatory 
cytokines into the circulation, which could cause 
further injury[1]. 
In early stages of human pancreatitis, activation of 
complement and subsequent release of C5a play 
significant roles in the recruitment of macrophages and 
polymorpho nuclear leukocytes. Active granulocytes 
and macrophages release proinflammatory cytokines in 
response to transcription factors such as nuclear 
factor(NF-Kb). Proinflammatory cytokines include 
TNF, IL-1, IL-6, IL-8, and platelet activating factor 
(PAF). Proinflammatory cytokines are followed by anti 
inflammatory cytokines (IL-2, IL-10, IL-11) that 
attempt to down regulate inflammation[2].Ulinastatin 
is a protease inhibitor extracted from human urine. 
Ulinastatin inhibits inflammatory markers: trypsin, 
pancreaticelastase. polumorphonuclear leukocyte 
elastase and the endotoxin stimulated production of 
TNF alpha and interleukin 1 ,8 and 6. It inhibits 
coagulation and fibrinolysis and promotes 
microperfusion[3].Our aim is to find out the 
effectiveness of addition of Ulinastatin to standard care 
in Indian subjects with acute pancreatitis.
 
Materials and methods 
 A concurrent observational study is done to evaluate 
the effect of addition of Ulinastatin to the standard 
treatment and its efficacy to reduce the serum amylase 
and lipase levels in patients with Acute Pancreatitis. It 
was done in inpatients of princess esra hospital and it 
was done in 6 months. We developed a patient’s data 
collection form to collect and analyse the patient’s 
health status on a daily basis.  
Inclusion Criteria: Patients of both the genders i.e. 
male and female. Patients with age of 18-75 years. 
Patients with alcoholic pancreatitis, in gastroenterology 
ward, with comorbidities, history of acute pancreatitis, 
who are alcoholics and smokers, patients meeting 
following criteria-Ransons prognostic criteria (<2-mild, 
2.5% mortality, >3 severe, 62% mortality). 
 Exclusion criteria were patients less than 18 years 
and more than 75 years of age, paediatric patients and 
pregnant and lactating women. 
At admission suspected cases were checked for BP, 
pulse rate, oxygen tension [PAO2], heart rate and 
temperature along with biochemical parameters serum 
amylase, serum lipase, s. sodium, S. potassium, S. 
chloride, s. creatinine, CBP, CT abd[plain], X-ray chest 
and ECG whenever required as per the age. 
History of alcoholism, gallstone disease, smoking, 
hypertriglyceraedemia, hypercalcaemia, CRF, history 
of pancreatitis were recorded wherever present. 
Biochemical parameters were recorded everyday till 
they touched normal. Out of 200 patients test group 
patients (n= 100) received ulinastatin 1lakh IU in 100 
ml dextrose/ NS- over 1 hr period twice a day for a 
period of 5 days along with standard medication, 
antibiotics, IV fluids, tramadol for pain, ryles tube 
aspiration, nil by mouth, PPI twice a day CT abdomen 
was done on day 0 and after completion of therapy 
(day 6). 
 
Results 
 
In our study total 60 patients are enrolled with acute 
pancreatitis following the inclusion criteria setup 
(n=60).Out of 60 patients,30 patient were given the 
drug and the other 30 were not given the drug. The 
patients who were given the drug showed sudden fall in 
their serum amylase and serum lipase levels showing 
the effective response of the drug. The other 30 
patients who were not given the drug gradually 
developed complications with no appropriate effect on 
serum amylase and lipase levels and evaluated the 
efficacy of Ulinastatin based on the results on these 60 
patients. The serum amylase and lipase levels are 
obtained once before the initiation of the drug to reach 
diagnosis and then after the addition of Ulinastatin to 
the ongoing standard therapy of  Acute Pancreatitic 
patients. The after serum amylase and lipase levels 
were taken after the use of Ulinastatin for a period of 
atleast 3-4 days. To know the efficacy of Ulinastatin 
with respect to serum amylase and serum lipase, we 
have applied Analysis of Variance(ANOVA) as the 
data collected fitted into the criteria of ANOVA and 
the results of which would fall under any one of the 
following hypothesis; Null Hypothesis(H0) : Addition 
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of Ulinastatin to standard care has no effect because of 
no significant change (calculated F value is less than 
the table F value).  Alternative Hypothesis: Addition of 
Ulinastatin to standard care has significant effect 
because of significant change (calculated F value is 
greater than the table F value). 
 
Fig 1: Age Distribution 
 
Table 1: Amylase and lipase ranges in ulinastatin group (test) and control group 
 
Number of cases Age range in yrs Gender Day 1 Day 2 Day 3 Day 4 
Serum Amylase (22-80 U/L) 
Test group: 30 22-75 M/F:50/50 63-3600 29-1009 39-327 40-110 
Control group: 30  24-72 M/F:55/45 87-2966 75-1240   76-1049 77-1121 
Serum Lipase (Upto 38 U/L) 
Test group: 30 22-75 M/F:50/50 44-1047 20-900 20-296 20-40 
Control group: 30  24-72 M/F:55/45 87-2966 75-1240   76-1049 77-1121 
 
Table 2: Mean serum amylase and lipase on the days of treatment 
 
serum amylase D1 D2 D3 D4 Row Total 
Control 686.16 515.72 400.27 296.42 1898.57 
Test 687.14 233.83 103.58 67.14 1091.69 
Total 1373.3 749.55 503.85 363.56 2990.26 
serum lipase 
Control 224.8 142.93 111.34 82.78 561.85 
Test 380.42 191.4 91.58 31 694.42 
Total 605.22 334.33 202.92 113.78 1256.25 
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Table 3: shows ANOVA-serum amylase and lipase 
 
Source of variation 
 
Sum of squares 
(SS) 
Degrees of 
freedom (df) 
Mean sum of 
squares(MSS) 
F ratio 
ANOVA-serum amylase 
Days (DSS) 299202.49 3 99734.16 10.44 
Treatment (TSS) 81381.92 1 81381.92 8.52 
Error (ESS) 28646.70 3 9548.9  
TSS 409231.11 7   
ANOVA-serum lipase 
Days (DSS) 68824.59 3 22941.53 5.45 
Treatment (TSS) 2203.13 1 2203.13 1.90 
Error (ESS) 12616.13 3 4205.37  
TSS  7   
The above results showed a significant change in serum amylase levels which is analysed  using Analysis of 
Variance(ANOVA). The calculated F value for serum amylase (n=60) obtained from the data collected during the 
study period from patients laboratory investigations reports amylase readings 10.44 and 8.52 w.r.t days and 
treatment. The calculated F value for serum amylase is greater than the table value for 60 subjects i.e,serum amylase 
F value 10.44 greater than table value 10.13,thus showing that there is a significant change in serum amylase levels 
in Ulinastatin group and therefore the null hypothesis can be rejected and alternate hypothesis can be accepted for 
our study. The calculated F value for serum lipase(n=60) obtained from obtained from the data collected during the 
study period from patients laboratory investigations reports lipase readings 5.45 and 1.90 w.r.t days and treatment. 
The calculated F value for serum lipase is less than the table value for 60 subjects i.e,serum lipase F value 5.45 less 
than table value 10.13,thus showing that there is no significant change in serum lipase levels in Ulinastatin group 
and therefore the null hypothesis can be accepted . Based on the above significant improvement in serum amylase 
and lipase,it can be concluded that addition of Ulinastatin to the standard care of Acute Pancreatitis is efficacious. 
Fig 2: Subjects in Ulinastatin group showing rapid response in their amylase and lipase levels while the 
subjects without the drug showed gradual decrease with complications arising during that period 
 
Discussion 
 
It is a concurrent and interventional study of ulinastatin 
in patients with acute pancreatitis which showed that 
IV administration of ulinastatin has better effect on 
serum amylase and lipase levels and with low 
significance of complications compared to control 
group. A few small studies published in chinese 
journals have shown lower mortality in patients treated 
with ulinastatin. Treatment with ulinastatin was 
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independently associated with decreased mortality 
compared to treatment with placebo group considering 
the baseline characteristics including age, gender, 
glasgow coma scale, specific organ failure, no.of 
organs failed,need for mechanical ventilation. Our 
results further collaborate these studies and suggest that 
treatment with ulinastatin may reduce mortality in 
acute pancreatitis in humans. In a study conducted in 
india for pancreatitis concluded that, 22-day all cause 
mortality in subjects with pancreatitis receiving 
ulinastatin was lower than those receiving placebo 
resulting in a 16% absolute  reduction in death risk and 
relative reduction of 85%. Our study aimed to show the 
effectiveness of ulinastatin in acute pancreatitis by 
comparing two groups of patient population in which 
one group was given the drug and other group was not. 
60 patients with acute pancreatitis following inclusion 
criteria set up (n=60). Out of 60 enrolled patients, 30 
patients were given ulinastatin while 30 patients were 
not given the drug. Our study was conducted in a 
multispeciality hospital in Gastroenterology 
department. Subjects enrolled were diagnosed with 
acute pancreatitis with high serum amylase and lipase 
levels. This study clearly documents the effect of 
ulinastatin on serum amylase and lipase levels. The 
patients given the drug showed quick decrease in their 
sr.amylase and lipase  levels compared to group which 
was not treated with the drug. No adverse effects were 
observed in any of the treatment groups.  
Abraham P, Rodriques J et.al[4] has studied the 
efficacy and safety of intravenous ulinastatin versus 
placebo along with standard supportive care in subjects 
with mild or severe acute pancreatitis. Of 135 
randomized subjects, 129 completed the study. 
Pancreatitis was due to alcohol intake in a majority 
(81%) of subjects. Efficacy was evaluated in subjects 
who had received at least 3 days (6 doses) of 
ulinastatin/placebo. They have concluded  that adverse 
events were significantly lower in subjects with severe 
pancreatitis in the ulinastatin group as compared to the 
placebo group (p = 0.00001) ,median hospitalization 
was shorter by one day in the ulinastatin group, there 
was no infusion-related adverse event and ulinastatin 
prevents new organ dysfunction and reduces mortality 
in subjects with severe pancreatitis. Shi Yao Chen,Ji 
Yao Wang[5] done multicenter randomized controlled 
clinical trial was performed.to assess of the 
effectiveness of Chinese-made ulinastatin in the 
treatment of patients with acute edematous pancreatitis 
(AEP) and acute hemorrhagic and necrotic pancreatitis 
(AHNP). A total of 94 patients with acute pancreatitis 
were enrolled into the study (50 males; 44 females). 
The study showed that the global effective rates of 
ulinastatin and cabexate in treating AEP were 100%, 
whereas the cured rate for ulinastatin was 83.3%, 
which was a little higher than that for cabexate 
(71.4%), but this difference was not statistically 
significant. Ulinastatin was shown to be effective in 
treating AEP and AHNP with few adverse 
effects.Efficacy of Ulinastatin regarding the Prevention 
of Post-ERCP Pancreatitis: A first multicenter 
randomized placebo controlled trial on ulinastatin for 
the prevention of post-ERCP pancreatitis was 
conducted. A series of 406 patients, who underwent 
diagnostic or therapeutic ERCP for the first time, was 
finally evaluated. Ulinastatin was administered 
intravenously immediately before ERCP for 10 
minutes. The incidence of hyperenzymemia was 
significantly lower in the ulinastatin group than in the 
placebo group (amylase, P=0.011; lipase, P=0.008). In 
addition, ulinastatin significantly reduced the rate of 
post-ERCP pancreatitis (6/204, 2.9%vs. 15/202, 7.4%; 
P=0.041). Using multivariate analysis, we found that 
therapeutic ERCP and the absence of ulinastatin 
administration were significant risk factors for the 
occurrence of post-ERCP pancreatitis.Ji Won Yoo, 
MD, et.al
6
  in their Prospective, Randomized, Placebo-
Controlled Trial. Preventive Effects of Ulinastatin on 
Post Endoscopic Retrograde 
Cholangiopancreatography Pancreatitis in High-Risk 
Patients: A total of 227 patients (mean age, 63 years; 
54% men) were randomized to receive placebo (n = 
108) or active drug (n = 119) immediately after ERCP 
and received active drug (100,000 U of ulinastatin) or 
placebo. Occurrence of post-ERCP pancreatitis and 
hyperamylasemia were compared between the 2 
groups. It was concluded that low-dose prophylactic 
treatment with ulinastatin immediately after ERCP did 
not show a beneficial influence on the incidence of 
post-ERCP pancreatitis and hyperamylasemia in high 
risk patients.
 
 Grzegorz Wallner et.al[7]morphological changes of 
the pancreas in course of acute pancreatitis during 
treatment with Ulinastatin. Evaluation of the 
histological preparations of various time groups 
showed significantly improved results after application 
of Ulinastatin, depending on the duration of the 
inflammation and the number of doses of the drug. It 
was concluded that application for the treatment of UTI 
leads to inhibition of the inflammatory process at the 
stage of pancreatic edema and in cases of severe 
necrotizing course limits the progression of the disease 
which gives grounds for its clinical use in humans. R. 
Maciejewskia, b et.al [8] selected biochemical 
parameters and ultrastructural picture of pancreas due 
to Ulinastatin treatment of experimental acute 
pancreatitis. They have combined the experimental 
model of severe, hemorrhagic form of acute 
 
Asian Pac. J. Health Sci., 2016; 3(4S):27-33                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Hassan and Hassan        ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(4S):27-33 
www.apjhs.com      32 
 
pancreatitis, and pharmacological treatment with a 
protease inhibitor. Subjects in the last group were 
administered UTI intraperitoneally 1 h after 
pancreatitis induction in an average standard dose of 
3000 units/animal. Statistically significant differences 
in the serum amylase and lipase activity between the 
UTI-treated and non-treated subjects were found. In the 
group of non-treated animals, there a profound 
destruction of cellular organelles was observed with a 
total degradation of nuceli, endoplasmatic reticulum 
and zymogen granules. However, in the UTI-treated 
subjects, pathological processes proceeded with the 
significantly slower pace and in much smaller 
quantities.
 
 Minoru Ohwada et.al[9]is comparative study was 
conducted to evaluate the effectiveness of contrast 
medium containing ulinastatin(UST) and water soluble 
Prednisolone(PDN) in preventing and decreasing the 
incidence of post ERCP pancreatitis. The post ERCP 
serum amylase level in some patients in the PDN and 
UST/PDN groups was lower than the pretreatment 
value. The results suggests that the use of contrast 
media containing PDN and UST/PDN is extremely 
effective in patients with chronic pancreatitis.
 
 
Chen Et al[10]debated he role of prophylactic 
ulinastatin in the prevention of post-endoscopic 
retrograde cholangiopancreatography (ERCP) 
pancreatitis. A meta-analysis of all published 
randomized clinical trials was performed to evaluate 
the efficacy of ulinastatin on post-ERCP pancreatitis. 
The incidence of post-ERCP pancreatitis was reduced 
by ulinastatin. Subsequent sensitivity and subgroup 
analyses produced conflicting results. Ulinastatin 
shows to be of value on preventing post-ERCP 
pancreatitis and hyperamylasemia for patients in 
average risk, when given intravenously at a dose of not 
less than 150,000 U, just before ERCP. More high-
quality trials are needed for further confirmation. A 
Prospective, multicentric, double blind, randomized 
phase III clinical study was conducted to compare the 
safety and efficacy of IV Ulinastain vs placebo along 
with supportive care in subjects with Acute or mild 
Pancreatitis. Of the 135 randomised subjects, 129 
completed the study(62 subjects in the mild groupand 
67 subjects in the severe group).The 22 day all cause 
mortality was reduced significantly from 18.8%in the 
placebo group to 2.8%in the Ulinastatin group in 
severe pancreatitis subjects. New onset organ failure 
decreased from 90% in placebo group to 34% in the 
Ulinastatin group this was statistically significant. 
Hospital stay was shorter in Ulinastatin group. The 
reduction of serum CRP was comparable in the two 
treatment groups. There was only one incidence if 
infusion related toxicity(transient rash).The number of 
adverse events. All of a non serious nature, were less in 
the study group vs control group(in mild patients 24 vs 
34and in severe patients 23 vs 45). Thus, treatment 
with Ulinastatin effectively reduced mortality and 
morbidity in patients with severe pancreatitis when use 
as an adjunctive therapy in addition to standard 
therapy. The reduction in mortality was accompanied 
by a shorter stay in the hospital and less 
complications[11]. 
 
Conclusion 
 
 The present study showed Ulinastatin added to 
standard care was demonstrated to provide superior 
safety and efficacy in Acute Pancreatitis patients  
compared to the group given only the standard 
treatment. Patients with Acute Pancreatitis (n=60) were 
enrolled based on the criteria setup and all of the 
completed the study. The strength of our study is the 
efficacy of the drug Ulinastatin to improve serum 
amylase and lipase levels efficiently thus reducing the 
duration of acute insult and preventing further 
complications. Out of 30 subjects in Ulinastatingroup 
,only 3 patients developed mild complications. 
Subjects (n=27) showed significant improvement in 
laboratory assessments. The incidence of complications 
was higher in the group which were not given the drug 
compared to the ulinastatin group. Hospital stay was 
shorter in the Ulinastatin group. These laboratory 
observations were accompanied with better symptom 
control preventing the progression to multiple organ 
dysfunction. Addition of the drug to the standard 
treatment significantly reduces the risk of episodes of 
worsening of the condition,providing sustained effect 
thereby reducing hospital stay. The overall results of 
our study suggests that Ulinastatin in the dose of 
5,00,000IU twice daily via NS result in 24 h consistent 
and sustained improvement for acute pancreatitis 
patients clinically. Thus the study concluded that 
addition of Ulinastatin to standard treatment of Acute 
Pancreatitis is effective in reducing morbidity and 
mortality in Indian subjects. 
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